Fairfield 1817 Black Rock Turnpike 469 W Putnam Ave Suite 204 Fairfield, CT 06824

Greenwich Ste 205, Greenwich, CT 06830





OCREVUS ZUNOVOTM

(ocrelizumab and hyaluronidase-ocsq)		Date:		
	PATIEN	T INFORMATI	ON	
Name:	Phone:		DOB:	SEX: M □ F □
□NKDA Allergies:			Weig	ght lbs/kg:
	PHYSICI	AN INFORMA	TION	
Physician Name:		Practice Name:		
Address:		Office Contact Name: Office Contact #:		
Phone: Fax:		Email (for updates):		
REFERRAL STATUS				
□New Referral □Referral Renewal	☐Medication/Order	Change □Benefit	ts Verification Only	☐Discontinuation Order
OCREVUS ZUNOVO is a CD20- • Relapsing forms of multiple sclerosis (MS), to progressive disease, in adults (1) • Primary progressive MS, in adults (1)	· ·	d syndrome, relapsing-re	emitting disease, and ac	tive secondary
□ ICD-10*:		WARNINGS AND PRECAUTIONS https://www.gene.com/download/pdf/ocrevus_zunovo_prescribing.pdf		
Dx Code: Dx Code: PRE-MEDICATION Tylenol PO 650mg		PATIENT WEIGHT lbs kg DOSAGE: Injection 920mg per 23ml (40 mg vial) FREQQUENCY: Every 6 months	g ocrelizumab and 23, g and 1,000 units/mL) for mont	000 units of hyaluronidase solution in a single-dose th
NOTES/ADDITIONAL COMMENTS: ORDERING PROVIDER		REQUIRED DO	CUMENTATION C	HECKLIST:
		Patient Demographics Insurance Card/Information Recent labs to include Hepatitis Panel and CBC, as well as CMP and quantitative, if available *Please send any other recent labs Recent Progress note and MRI of Brain Other		
Signature X		Date		
Provider	Phone	Fax		
			-	